Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical.

Business Wire • Aug 31, 2026

Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September.

Business Wire • Aug 27, 2026

Transcat, Inc. (TRNS) Q1 2027 Earnings Call Transcript

Transcat, Inc. (TRNS) Q1 2027 Earnings Call Transcript

Seeking Alpha • Aug 5, 2026

Transcat Q1 Earnings Call Highlights

Transcat NASDAQ: TRNS reported first-quarter fiscal 2027 revenue of $92.9 million, up 22% from a year earlier, as both its calibration services and distribution segments posted double-digit growth. The company said demand remained strong across its regulated end markets, including life sciences, aerospace and defense, and energy.

MarketBeat • Aug 5, 2026

Transcat Reports Strong Fiscal First Quarter 2027 Financial Results with Double-Digit Service Organic Revenue* Growth and Service Gross Margin Expansion

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal First Quarter 2027 Results with Double-Digit Service Organic Revenue Growth and Service Gross Margin Expansion.

Business Wire • Aug 4, 2026

Transcat, Inc. (TRNS) Q1 Earnings and Revenues Top Estimates

Transcat, Inc. (TRNS) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.59 per share a year ago.

Zacks Investment Research • Aug 4, 2026

Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat to Host First Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, August 4, 2026 at 4:30 p.m. Eastern Time.

Business Wire • Jul 16, 2026

Transcat: Mission Critical Company With A Strong Moat

Transcat, Inc. is rated BUY, leveraging recurring revenue from government-mandated calibration services and a strong competitive moat. TRNS's growth is driven by high-margin services, strategic M&A, and recent expansion into Latin America, targeting life sciences and regulated industries. Despite a 58% YTD share price gain, TRNS trades at 18x forward EV/EBITDA, well below its historical peak valuation multiples.

Seeking Alpha • Jun 25, 2026

Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer.

Business Wire • Jun 22, 2026

2 Instruments Stocks Likely to Beat Short-Term Industry Challenges

The increasing adoption of industrial automation, focus on higher energy efficiency and optimum resource utilization should drive the Zacks Instruments ??? Control industry.

Zacks Investment Research • Jun 17, 2026